non-financial development institution
major organizer of congress and exhibition events
Welcome!
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Вегнер Макс Петер
Max Peter Wegner
Senior Vice President, Head of Regulatory Affairs, Pharmaceuticals Division, Bayer AG
Biography
Max leads the global Regulatory Affairs organization for Pharmaceuticals and is based in Wuppertal, Germany.

A pharmacist by training, Max studied at the Friedrich-Wilhelms University of Bonn. Max graduated as Dr. rer. nat. in 1996 at the Preclinical Institute of Pharmacology of Bayer AG, Wuppertal / University of Bonn with the title of his doctorial dissertation being “Pharmacological and biochemical evaluations with the Neutral Endopeptidase Inhibitors Ecadotril and (S)-Thiorphan“. In 1997 he was authorized for further education in „Drug Information“.

He is a lecturer of DGRA (Deutsche Gesellschaft Regulatory Affairs) at Rheinische Friedrich-Wilhelms Universität Bonn, Germany as well as the Forum Institute (“FORUM Institut für Management GmbH”, Heidelberg, Germany).

He joined Bayer in 1996 as Global Regulatory Dossier Manager in Wuppertal with various responsibilities for Products of the Anti-Infectives group.

In 2000 Max became Global Project Manager within Global Strategic Marketing leading Anti-Infective projects.

Between 2002 and 2007 he served as Therapeutic Area Head in Global Regulatory Affairs (GRA) being responsible for regulatory strategies worldwide.

2007 Max was named Vice President - Global Regulatory Affairs Head Hematology/Cardiology & Specialised Therapeutics and in 2008 he took over the responsibility as Global Regulatory Affairs Head International.

Starting in October 2009 he has been working for almost 5 years as Global Regulatory Affairs Head General Medicine where he built and set up a new General Medicine department within Global Regulatory Affairs.

Between April and September 2011 Max has been appointed interim Head GRA Asia, Beijing, Asia, and between November 2012 and July 2013 interim Head GRA US Montville, US, both positions while maintaining global General Medicine responsibilities.

In June 2014 Max was named Senior Vice President Therapeutic Area General Medicine and in 2017 the therapeutic area organisations Hematology and Ophthalmology have been added.

Since January 2018 Max leads the global Regulatory Affairs organization of Bayer Pharmaceuticals, and Consumer Health until it had been reintegrated into Consumer Health at the end of 2018, and is responsible for all regulatory strategies worldwide as well as maintenance activities and other projects.